The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …

Although chimeric antigen receptor (CAR) T cells have altered the treatment landscape for B
cell malignancies, the risk of on-target, off-tumour toxicity has hampered their development …

Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …

Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer,
negatively expresses estrogen receptor, progesterone receptor, and the human epidermal …

Immune cells are being engineered to recognize and respond to disease states, acting as a
“living drug” when transferred into patients. Therapies based on engineered immune cells …

A major challenge facing tumor-antigen targeting therapies such as chimeric antigen
receptor (CAR)–T cells is the identification of suitable targets that are specifically and …

T cells are the major arm of the immune system responsible for controlling and regressing
cancers. To identify genes limiting T cell function, we conducted genome-wide CRISPR …

Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in
2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women …

Chimeric antigen receptor (CAR) T cells can revolutionize cancer medicine. However,
overactivation, lack of tumor-specific surface markers, and antigen escape have hampered …